How to Treat HR+/HER2-Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story

被引：10

作者：

Cogliati, Viola ^{[1
]}

Capici, Serena ^{[1
]}

Pepe, Francesca Fulvia ^{[1
]}

di Mauro, Pierluigi ^{[2
]}

Riva, Francesca ^{[2
]}

Cicchiello, Federica ^{[2
]}

Maggioni, Claudia ^{[2
]}

Cordani, Nicoletta ^{[3
]}

Cerrito, Maria Grazia ^{[3
]}

Cazzaniga, Marina Elena ^{[1
,3
]}

机构：

[1] ASST Monza, Phase Res Ctr 1, I-20900 Monza, MB, Italy

[2] ASST Monza, Oncol Unit, I-20900 Monza, MB, Italy

[3] Univ Milano Bicocca, Sch Med & Surg, I-20900 Monza, MB, Italy

来源：

LIFE-BASEL | 2022年 / 12卷 / 03期

关键词：

metastatic breast cancer; CDK4; 6; inhibitors; therapy resistance; treatment sequencing; KINASE; 4/6; INHIBITOR; ENDOCRINE THERAPY; PALBOCICLIB; RESISTANCE; FULVESTRANT; COMBINATION; MULTICENTER; ABEMACICLIB; STRATEGIES; RIBOCICLIB;

D O I：

10.3390/life12030378

中图分类号：

Q [生物科学];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

CDK4/6 inhibitors in association with endocrine therapy represent the best therapeutic choice for either endocrine-sensitive or resistant hormone-receptor-positive advanced breast cancer patients. On the contrary, the optimal therapeutic strategy after the failure of CDK4/6 inhibitors-based treatment still remains an open question worldwide. In this review, we analyze the most studied mechanisms of resistance to CDK4/6 inhibitors treatment, as well as the most significant results of retrospective and prospective trials in the setting of progression after CDK4/6 inhibitors, to provide the reader a comprehensive overview from both a preclinical and especially a clinical perspective. In our opinion, an approach based on a deeper knowledge of resistance mechanisms to CDK4/6 inhibitors, but also on a careful analysis of what is done in clinical practice, can lead to a better definition of prospective randomized trials, to implement a personalized sequence approach, based on molecular analyses.

引用

页数：17

共 74 条

[1] Characterizing demographics, clinical, and genomic characteristics for US patients with HR+, HER2-metastatic breast cancer following progression on a CDK4 and 6 inhibitor. [J].

Andre, Fabrice ;

Aggarwal, Amit ;

Rao, Xi ;

Chen, Yongmei ;

Beyrer, Julie Kay ;

Smyth, Emily Nash ;

Guimaraes, Claudia Morato ;

Litchfield, Lacey ;

Bowman, Lee .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

[2] Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer [J].

Andre, Fabrice ;

Ciruelos, Eva ;

Rubovszky, Gabor ;

Campone, Mario ;

Loibl, Sibylle ;

Rugo, Hope S. ;

Iwata, Hiroji ;

Conte, Pierfranco ;

Mayer, Ingrid A. ;

Kaufman, Bella ;

Yamashita, Toshinari ;

Lu, Yen-Shen ;

Inoue, Kenichi ;

Takahashi, Masato ;

Papai, Zsuzsanna ;

Longin, Anne-Sophie ;

Mills, David ;

Wilke, Celine ;

Hirawat, Samit ;

Juric, Dejan .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (20) :1929-1940

[3]

Baird R, 2021, CANCER RES, V81

[4]

Bardia A., 2021, P 2021 SAN ANT BREAS

[5] Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR+/HER2- Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1) [J].

Bardia, Aditya ;

Hurvitz, Sara A. ;

DeMichele, Angela ;

Clark, Amy S. ;

Zelnak, Amelia ;

Yardley, Denise A. ;

Karuturi, Meghan ;

Sanft, Tara ;

Blau, Sibel ;

Hart, Lowell ;

Ma, Cynthia ;

Rugo, Hope S. ;

Purkayastha, Das ;

Moulder, Stacy .

CLINICAL CANCER RESEARCH, 2021, 27 (15) :4177-4185

[6] Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer [J].

Bardia, Aditya ;

Kaklamani, Virginia ;

Wilks, Sharon ;

Weise, Amy ;

Richards, Donald ;

Harb, Wael ;

Osborne, Cynthia ;

Wesolowski, Robert ;

Karuturi, Meghan ;

Conkling, Paul ;

Bagley, Rebecca G. ;

Wang, Yamei ;

Conlan, Maureen G. ;

Kabos, Peter .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (12) :1360-+

[7] Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer [J].

Baselga, Jose ;

Campone, Mario ;

Piccart, Martine ;

Burris, Howard A., III ;

Rugo, Hope S. ;

Sahmoud, Tarek ;

Noguchi, Shinzaburo ;

Gnant, Michael ;

Pritchard, Kathleen I. ;

Lebrun, Fabienne ;

Beck, J. Thaddeus ;

Ito, Yoshinori ;

Yardley, Denise ;

Deleu, Ines ;

Perez, Alejandra ;

Bachelot, Thomas ;

Vittori, Luc ;

Xu, Zhiying ;

Mukhopadhyay, Pabak ;

Lebwohl, David ;

Hortobagyi, Gabriel N. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (06) :520-529

[8] First- and second-line treatment strategies for hormone-receptor (HR)-positive HER2-negative metastatic breast cancer: A real-world study [J].

Basile, Debora ;

Gerratana, Lorenzo ;

Corvaja, Carla ;

Pelizzari, Giacomo ;

Franceschin, Giorgia ;

Bertoli, Elisa ;

Palmero, Lorenza ;

Zara, Diego ;

Alberti, Martina ;

Buriolla, Silvia ;

Da Ros, Lucia ;

Bonotto, Marta ;

Mansutti, Mauro ;

Spazzapan, Simon ;

Cinausero, Marika ;

Minisini, Alessandro Marco ;

Fasola, Gianpiero ;

Puglisi, Fabio .

BREAST, 2021, 57 :104-112

[9] 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) [J].

Cardoso, F. ;

Paluch-Shimon, S. ;

Senkus, E. ;

Curigliano, G. ;

Aapro, M. S. ;

Andre, F. ;

Barrios, C. H. ;

Bergh, J. ;

Bhattacharyya, G. S. ;

Biganzoli, L. ;

Boyle, F. ;

Cardoso, M-J ;

Carey, L. A. ;

Cortes, J. ;

El Saghir, N. S. ;

Elzayat, M. ;

Eniu, A. ;

Fallowfield, L. ;

Francis, P. A. ;

Gelmon, K. ;

Gligorov, J. ;

Haidinger, R. ;

Harbeck, N. ;

Hu, X. ;

Kaufman, B. ;

Kaur, R. ;

Kiely, B. E. ;

Kim, S-B ;

Lin, N. U. ;

Mertz, S. A. ;

Neciosup, S. ;

Offersen, B., V ;

Ohno, S. ;

Pagani, O. ;

Prat, A. ;

Penault-Llorca, F. ;

Rugo, H. S. ;

Sledge, G. W. ;

Thomssen, C. ;

Vorobiof, D. A. ;

Wiseman, T. ;

Xu, B. ;

Norton, L. ;

Costa, A. ;

Winer, E. P. .

ANNALS OF ONCOLOGY, 2020, 31 (12) :1623-1649

[10]

Cataldo M.L., 2021, CLIN CANCER RES, V27, P4870, DOI [10.1158/1078-0432.CCR-19-4191, DOI 10.1158/1078-0432.CCR-19-4191]

← 1 2 3 4 5 6 7 8 →